Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Neurofibroma × Mn-PyC3A × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroma, Acoustic 1 Neuroinflammatory Diseases 1 Neurofibroma 1 Neurilemmoma 1 Neoplasms 1 Multiple Sclerosis 1 Meningioma 1 Glioma 1 Central Nervous System Neoplasms 1 Brain Neoplasms 1

Interventions

mirdametinib 1 Mn-PyC3A 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06322342 2025-12-26

Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent

Reveal Pharmaceuticals Inc.

Phase 2 Completed

Neuroinflammatory Diseases, Brain Neoplasms, Glioma, Meningioma, Multiple Sclerosis, Neoplasms, Neurilemmoma, Neurofibroma, Neuroma, Acoustic, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡